Skip to search boxSkip to navigationSkip to main content

Pathobiont-driven antibody sialylation through IL-10 undermines vaccination

  • Chih Ming Tsai(corresponding author)
    ,
  • Irshad A. Hajam
    ,
  • J. R. Caldera
    ,
  • ,
  • Cesia Gonzalez
    ,
  • Xin Du
*Corresponding author for this work
  • University of California at San Diego
    ,
  • ,
  • Rady Children's Hospital
    ,
  • San Diego State University
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

The pathobiont Staphylococcus aureus (Sa) induces nonprotective antibody imprints that underlie ineffective staphylococcal vaccination. However, the mechanism by which Sa modifies antibody activity is not clear. Herein, we demonstrate that IL-10 is the decisive factor that abrogates antibody protection in mice. Sa-induced B10 cells drive antigen-specific vaccine suppression that affects both recalled and de novo developed B cells. Released IL-10 promotes STAT3 binding upstream of the gene encoding sialyltransferase ST3gal4 and increases its expression by B cells, leading to hyper-α2,3sialylation of antibodies and loss of protective activity. IL-10 enhances α2,3sialylation on cell-wall–associated IsdB, IsdA, and MntC antibodies along with suppression of the respective Sa vaccines. Consistent with mouse findings, human anti-Sa antibodies as well as anti-pseudomonal antibodies from cystic fibrosis subjects (high IL-10) are hypersialylated, compared with anti–Streptococcus pyogenes and pseudomonal antibodies from normal individuals. Overall, we demonstrate a pathobiont-centric mechanism that modulates antibody glycosylation through IL-10, leading to loss of staphylococcal vaccine efficacy.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Article number

e179563

Journal (Volume, Issue Number)

Journal of Clinical Investigation (Volume 134, Issue 24)

Publication milestones

  • Published - 12/16/2024

Publication status

Published - 12/16/2024

ISSN

0021-9738

Publication IDs

  • Scopus: 85212343907
  • PubMed: 39680460
  • ORCID: /0000-0001-6514-5612/work/177386212

Publication metrics

Metrics

Scopus
citations
Fractional count
1
Fractional count
0.05
Fractional count
18
Fractional count
0.95
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Captures
18
Mentions
9
Citation count
12

Funding Details

We thank Shui-Hua Wang for inputs on glycan analysis and S. Secore (Merck) for providing the Becker WT and IsdB/HarA mutant strains. The authors acknowledge funding from the National Institute of Health (grants R01AI127406, R01AI144694, R01AI181321, R01AI179098 and R35 GM119850) and the Novo Nordisk Foundation (NNF20SA0066621). We thank Shui-Hua Wang for inputs on glycan analysis and S. Sec-ore (Merck) for providing the Becker WT and IsdB/HarA mutant strains. The authors acknowledge funding from the National Institute of Health (grants R01AI127406, R01AI144694, R01AI181321, R01AI179098 and R35 GM119850) and the Novo Nordisk Foundation (NNF20SA0066621).
FundersFunding numbers
Merck
-
NIH
R01AI179098, R01AI127406, R35 GM119850, R01AI144694, R01AI181321
NNF
NNF20SA0066621